Xie Jian-Hua, Zhu Rui-Rui, Zhao Li, Zhong Yu-Cheng, Zeng Qiu-Tang
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Department of Gastroenterology, Hubei Provincial Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan, 430022, China.
Curr Med Sci. 2020 Aug;40(4):662-670. doi: 10.1007/s11596-020-2238-5. Epub 2020 Aug 29.
In various autoimmune diseases, Galecin-9 (Gal-9) has been shown to regulate the T-cell balance by decreasing Th1 and Th17, while increasing the number of regulatory T cells (Tregs). However, the role of Gal-9 in the patients with acute coronary syndrome (ACS) and chronic kidney disease (CKD) remains unclear. This study aims to measure the Gal-9 levels in serum and peripheral blood mononuclear cells (PBMCs) in patients with ACS plus CKD and examine their clinical implication. The serum levels of Gal-9 were determined by enzyme-linked immunosorbent assay (ELISA), the expression levels of Gal-9, Tim-3, and Foxp3 mRNA in PBMCs were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR), and the expression of Gal-9 on the surface of PBMCs and in PBMCs was analyzed by flow cytometry. Furthermore, the correlation of serum Gal-9 levels with anthropometric and biochemical variables in patients with ACS plus CKD was analyzed. The lowest levels of Gal-9 in serum and PBMCs were found in the only ACS group, followed by the ACS+CKD group, and the normal coronary artery (NCA) group, respectively. Serum Gal-9 levels were increased along with the progression of glomerular filtration rate (GFR) categories of G1 to G4. Additionally, serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein (hs-CRP), estimated GFR (eGFR), and lipoprotein(a), but positively with creatinine, age, osmotic pressure, and blood urea nitrogen (BUN). Notably, serum Gal-9 was independently associated with hs-CRP, osmotic pressure, and lipoprotein(a). Furthermore, serum Gal-9 levels were elevated in patients with type 2 diabetes (T2DM) and impaired glucose tolerance (IGT) in ACS group. It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD, and hs-CRP, eGFR, osmotic pressure and T2DM may have an influence on serum Gal-9 levels.
在各种自身免疫性疾病中，已证明半乳糖凝集素-9（Gal-9）可通过减少Th1和Th17来调节T细胞平衡，同时增加调节性T细胞（Tregs）的数量。然而，Gal-9在急性冠状动脉综合征（ACS）和慢性肾脏病（CKD）患者中的作用仍不清楚。本研究旨在测定ACS合并CKD患者血清和外周血单个核细胞（PBMCs）中的Gal-9水平，并探讨其临床意义。采用酶联免疫吸附测定（ELISA）法测定血清Gal-9水平，通过实时逆转录-聚合酶链反应（RT-PCR）检测PBMCs中Gal-9、Tim-3和Foxp3 mRNA的表达水平，并用流式细胞术分析PBMCs表面和细胞内Gal-9的表达。此外，分析了ACS合并CKD患者血清Gal-9水平与人体测量学和生化指标的相关性。血清和PBMCs中Gal-9水平最低的分别是单纯ACS组，其次是ACS+CKD组，冠状动脉正常（NCA）组。血清Gal-9水平随肾小球滤过率（GFR）从G1到G4类别的进展而升高。此外，血清Gal-9水平与高敏C反应蛋白（hs-CRP）、估算肾小球滤过率（eGFR）和脂蛋白（a）呈负相关，但与肌酐、年龄、渗透压和血尿素氮（BUN）呈正相关。值得注意的是，血清Gal-9与hs-CRP、渗透压和脂蛋白（a）独立相关。此外，ACS组中2型糖尿病（T2DM）和糖耐量受损（IGT）患者的血清Gal-9水平升高。提示单纯ACS患者以及ACS合并CKD患者血清和PBMCs中Gal-9水平降低，hs-CRP、eGFR、渗透压和T2DM可能对血清Gal-9水平有影响。
